HUMAN IMMUNE RESPONSE TO POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES

多糖蛋白结合疫苗的人体免疫反应

• 批准号: 3919310
• 负责人: R SCHNEERSON
• 金额: --
• 依托单位: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3919310
• 关键词: Haemophilus influenzae; Haemophilus influenzae vaccines; Macaca mulatta; Scandinavian country; antibacterial antibody; bacterial antigens; bacterial capsules; bacterial meningitis; bacterial polysaccharides; bactericidal immunity; child (0-11); drug adverse effect; enzyme linked immunosorbent assay; human age group; human subject; immunization; immunoconjugates; immunoglobulins; immunological substance; infant human (0-1 year); laboratory mouse; radioimmunoassay; tetanus toxoid

The age-related and T-independent properties, of Haemophilus influenzae type b capsular polysaccharide (Hib) and other polysaccharides of invasive organisms, limit their protective actions in infants and children, that age group which the highest attack rate of diseases due to these encapsulated pathogens. Organic synthetic schemes, that bound Hib and other capsular polysaccharides to tetanus toxoid, were devised in order to both increase the immunogenicity of and confer T-cell dependence (booster effect) to these protective antigens. Based upon ours, and others work in the field, a conjugated Hib vaccine, prepared by our original method, was licensed by the FDA for universal use in children older than 18 months of age. The safety and immunologic properties of our Hib-TT vaccine has been investigated in 18 month olds and now to two to three month old infants. The preliminary results show that protective levels of antibodies were induced in the young infants after two injections. Effectiveness study of this vaccine in infants and children in Charlotte, N.C. and Goteborg, Sweden are being planned.

嗜血杆菌的年龄相关性和T非依赖性 B型流感衣壳多糖(Hib)等 入侵生物的多糖限制了它们的保护作用 在婴幼儿行动中，哪个年龄段的人最多 这些被包裹的病原体引起的疾病的发病率。 有机合成方案，结合Hib和其他胶囊 破伤风类毒素多糖的设计，是为了既 增强T细胞的免疫原性并增强其依赖性 (助推器效应)对这些保护性抗原。在我们的基础上， 和其他在现场工作的人，准备了一种结合的Hib疫苗 通过我们最初的方法，获得了FDA的普遍使用许可 对于18个月以上的儿童。安全和 对我们研制的Hib-TT疫苗的免疫学特性进行了研究 在18个月大的婴儿，现在到2到3个月大的婴儿。这个 初步结果表明，抗体的保护水平是 在两次注射后的婴幼儿中诱导。有效性 这种疫苗在北卡罗来纳州夏洛特市的婴儿和儿童中的研究。 瑞典的哥德堡也在规划之中。